Javier Segovia Cubero-rekin lankidetzan egindako argitalpenak (9)

2019

  1. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

    JACC: Heart Failure, Vol. 6, Núm. 6, pp. 452-462

2014

  1. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?

    International Journal of Cardiology, Vol. 171, Núm. 1, pp. 15-23

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184

  2. Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

    European Journal of Heart Failure, Vol. 15, Núm. 8, pp. 877-884

  3. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation

    Clinical Transplantation, Vol. 27, Núm. 6

2012

  1. Survival in pulmonary hypertension in Spain: Insights from the Spanish registry

    European Respiratory Journal, Vol. 40, Núm. 3, pp. 596-603

2008

  1. Standards of care in pulmonary hypertension

    Revista Espanola de Cardiologia, Vol. 61, Núm. 2, pp. 170-184

  2. Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)

    Archivos de Bronconeumologia, Vol. 44, Núm. 2, pp. 87-99